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Abstract  
Chronic graft-versus-host disease (GVHD) remains a major late complication of 
allogeneic bone marrow transplantation (BMT). In a previous study, impaired thymic 
negative selection of the recipients permitted the emergence of pathogenic T cells that cause 
chronic GVHD using MHC class II-deficient (H2-Ab1 KO) B6 into C3H model and CD4+ T 
cells isolated from chronic GVHD mice caused chronic GVHD when administered into the 
secondary recipients. In this study, we evaluated the kinetics of regulatory T cell (Treg) 
reconstitution in wild type B6 into C3H model. After myeloablative conditioning, host Tregs 
disappeared rapidly, followed by expansion of Tregs derived from the donor splenic T cell 
inoculum. However, the donor splenic T cell-derived Treg pool contracted gradually and was 
almost completely replaced by newly generated donor bone marrow (BM)-derived Tregs in 
the late post-transplant period. Next, we compared the effects of cyclosporine (CSA) and 
mammalian target of rapamycin (mTOR) inhibitors on Treg reconstitution. Administration of 
CSA significantly impaired Treg reconstitution in the spleen and thymus. In contrast, 
BM-derived Treg reconstitution was not impaired in mTOR inhibitor-treated mice. 
Histopathological examination indicated that mice treated with CSA, but not mTOR 
inhibitors, showed pathogenic features of chronic GVHD on day 120. Mice treated with CSA, 
but not mTOR inhibitors until on day 60 developed severe chronic GVHD followed by 
adoptive transfer of the pathogenic CD4+ T cells isolated from H2-Ab1 KO into C3H model. 
These findings indicated that long-term use of CSA impairs reconstitution of BM-derived 
Tregs and increases the liability to chronic GVHD. The choice of immunosuppression, such 
as calcineurin inhibitor-free GVHD prophylaxis with mTOR inhibitor, may have important 
implications for the control of chronic GVHD after BMT. 
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Introduction 
Chronic GVHD is the most serious late complication after allogeneic HSCT, but the 
pathophysiology and treatment strategy of chronic GVHD remain poorly defined (1-3). 
GVHD prophylaxis using calcineurin inhibitors, such as cyclosporine (CSA) and tacrolimus, 
reduces the expansion of effector T cells by blocking interleukin (IL)-2 and prevents acute 
GVHD, but fails to reduce chronic GVHD (4, 5). Administration of CSA for up to 24 months, 
longer than the standard 6 months of CSA, also did not decrease the risk of chronic GVHD 
(6). Several studies have indicated that the efficacy and safety of mammalian target of 
rapamycin (mTOR) inhibitor, rapamycin (RAPA), in refractory chronic GVHD patients 
(7-10). However, a recent randomized trial showed that the combination of RAPA and 
tacrolimus as GVHD prophylaxis failed to reduce chronic GVHD compared with tacrolimus 
and methotrexate (11). 
CD4+CD25+Foxp3+ regulatory T cells (Tregs) have been shown to play an important 
role in the establishment of tolerance between recipient tissues and donor-derived 
immunity. A series of animal studies indicated that Tregs in the inoculum can prevent acute 
GVHD when injected together with donor T cells (12-14). Based on the role of Tregs in the 
prevention of GVHD and on their dependence on IL-2, there is considerable concern 
regarding the impact of blocking IL-2 signaling or IL-2 production by the 
immunosuppressive agents used for prophylaxis of GVHD. Zeiser et al. reported that Tregs 
showed relative resistance to RAPA as a result of reduced usage of the mTOR pathway and 
functional PTEN, a negative regulator of the phosphatidyl-inositol 3-kinase 
(PI3K)/Akt/mTOR pathway in Tregs compared with conventional T cells (15). In contrast to 
CSA, RAPA allowed expansion of adoptively transferred Treg cells and led to reduction of 
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alloreactive T cell expansion when animals received Treg treatment in combination with 
RAPA. They also showed that a combination of RAPA plus IL-2 increased both expansion of 
donor natural Tregs and conversion of induced Tregs from donor conventional T cells, and 
suppressed acute GVHD (16). These animal data suggest that RAPA and CSA have 
differential impacts on peripheral Tregs following BMT. 
IL-2 signaling is pivotal for Treg homeostasis in the periphery and is also essential for 
naturally occurring Treg development in the thymus (17-19). T cell repopulation following 
BMT is composed of two subsets: T cells derived from the donor splenic T cell inoculum and 
newly arising T cells from bone marrow (BM) inoculum. It has been shown that Tregs from 
the former pathway play an important role in acute GVHD, whereas, no previous study 
evaluated whether use of CSA for an extended period affects donor BM-derived Treg 
generation. We hypothesized that BM-derived Tregs comprise the long-term peripheral Treg 
pool and that CSA, but not mTOR inhibitors, causes impaired BM-derived Treg 
reconstitution, which has a negative impact on chronic GVHD. In the present study, we 
therefore evaluated effects of different immunosuppressants on two distinct Treg expansion 
reconstitution pathways and on the development of chronic GVHD. 
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Materials and methods 
Mice 
Female C57BL/6 (B6: H-2b, CD45.2+) and C3H/HeN (C3H: H-2k) mice were purchased 
from Charles River Japan (Yokohama, Japan) or from the Okayama University mouse colony 
(Okayama, Japan). B6-Ly5a (H-2b, CD45.1+) and C3.SW (H-2b, CD45.2+) mice were 
purchased from Jackson Laboratory (Bar Harbor, ME). B6-background MHC class 
II-deficient H2-Ab1−/− mice (B6.129-H2-Ab1tm1Gru N12) were from Taconic Farms 
(Germantown, NY) (20). Mice between 8 and 18 weeks of age were maintained under 
specific pathogen-free conditions and received normal chow and hyperchlorinated drinking 
water after transplantation. All experiments involving animals were approved by the 
Institutional Animal Care and Research Advisory Committee, Okayama University Advanced 
Science Research Center. 
 
Bone marrow transplantation (BMT) 
Mice received transplants according to the standard protocol described previously (21, 
22). Briefly, recipient mice received two split doses of either 500 cGy (allogeneic C3H and 
C3.SW recipients) or 650 cGy (syngeneic B6 recipients) total-body irradiation (TBI) 3 – 4 h 
apart. Recipients were injected with 10×106 T cell-depleted bone marrow (TCD-BM) cells 
plus 1 or 2×106 whole spleen cells from B6 donors. [H2-Ab1−/− → C3H] chimeras were 
produced by reconstituting lethally irradiated C3H mice with 5×106 TCD-BM cells from 
H2-Ab1−/− mice, as described previously (23). T cell depletion was performed using 
anti-CD90–microbeads and an AutoMACS system (Miltenyi Biotec, Auburn, CA) according 
to the manufacturer’s instructions. Donor cells were injected intravenously into the recipients 
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on day 0. 
 
Immunosuppressive treatment 
Rapamycin (RAPA) was purchased from Toronto Research Chemicals Inc. (North York, 
ON, Canada). Everolimus (RAD) and CSA were synthesized and provided by Novartis 
Pharma AG (Basel, Switzerland). Everolimus emulsion was dissolved in distilled water at a 
concentration of 625 µg/ml and administered to recipients by oral gavage at a dose of 5 
mg/kg. RAPA and CSA were given as suspensions in carboxymethylcellulose sodium salt: 
CMC (C5013; Sigma-Aldrich, St. Louis, MO) at a final concentration of 0.2% CMC. RAPA 
and CSA were administered to recipients by peritoneal injection at doses of 0.5 and 20 mg/kg, 
respectively(15, 24). Immunosuppressive treatments were performed once daily, starting on 
day 0 and continuing until death or end of the observation period (day 110 – 125). 
 
Adoptive transfer 
Splenocytes were isolated from [H2-Ab1−/− → C3H] chimeras 6 – 11 weeks after 
TCD-BMT. CD4+ T cells were negatively selected from splenocytes by depletion of CD8+, 
DX5+, CD11b+, Ter-119+, and B220+ cells using the AutoMACS system, as described 
previously (23). A total of 2×107 CD4+ T cells per mouse were injected intravenously into 
recipients following immunosuppressive therapy for 70 days after BMT. 
 
Assessment of GVHD 
Following BMT, survival was monitored daily, and weight changes were assessed twice 
per week. The degree of clinically acute GVHD was assessed twice per week using a scoring 
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system that sums changes in five clinical parameters: weight loss, posture, activity, fur 
texture, and skin integrity (maximum index, 10) as described previously (22). Shaved skin 
from the interscapular region (approximately 2 cm2), liver, and salivary gland specimens of 
recipients were fixed in 10% formalin, embedded in paraffin, sectioned, mounted on slides, 
and stained with hematoxylin and eosin. Skin slides were scored on the basis of dermal 
fibrosis, fat loss, inflammation, epidermal interface changes, and follicular drop-out (0 – 2 for 
each category; the maximum score was 10) (21). Liver slides were scored based on bile duct 
injury and inflammation (0 – 4 for each category), and the maximum score was 8 (25). 
Salivary gland slides were scored based on atrophy and inflammation (0 – 3 for each 
category), and the maximum score was 6. All slides were scored by pathologists (T.K. and 
T.T.) blind to experimental group. 
 
Immunohistochemistry 
Immunohistochemical staining for Foxp3 and CD3 was performed using the high 
polymer (HISTOFINE simple stain, NICHIREI, Tokyo, Japan) method. Anti-Foxp3 
(eBioscience) and anti-CD3 (Abcam, Cambridge, MA) were used to identify Tregs and 
effector T cells, respectively. 
 
Flow cytometry 
The mAbs used were unconjugated anti-CD16/32(2.4G2); FITC-, PE-, PerCP-, or 
APC-conjugated anti-mouse CD4, CD25, CD45.1, CD45.2, H-2b, H-2d (BD Pharmingen, San 
Diego, CA); and Foxp3 (eBioscience, San Diego, CA), as described previously (26). A Foxp3 
staining kit™ (eBioscience) was used for intracellular staining. Cells were analyzed on a 
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FACSAria flow cytometer with FACSDiva software (BD Immunocytometry Systems, San 
Diego, CA). 
 
Mixed leukocyte reaction 
CD4+CD25– T cells, CD4+CD25+ T cells, and CD11c+ DC were magnetically separated 
by AutoMACS using microbeads from a CD4+CD25+ regulatory T cell isolation kit and 
CD11c microbeads. CD4+CD25– T cells (5×104 per well) together with various numbers of 
CD25+CD4+ T cells (0 – 5×104 per well) were cultured with irradiated (30 Gy) CD11c+ DC as 
stimulators for 72 h in 96-well round-bottomed plates. Cells were pulsed with 3H-thymidine 
(1 μCi [0.037 MBq] per well) for a further 16 h (27). Proliferation was determined using 
Topcount NXT (Packard Instruments, Meriden, CT). 
 
Statistics 
Data are given as means ± SEM. The survival curves were plotted using Kaplan–Meier 
estimates. Group comparisons of pathology scores were performed using the Mann–Whitney 
U test. Comparative analysis of cell ratios was performed by the unpaired two-tailed 
Student’s t-test or Welch’s t-test. In all analyses, P < 0.05 was taken to indicate statistical 
significance.
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Results  
Kinetics of Treg reconstitution after allogeneic bone marrow transplantation 
We first examined whether Tregs intermixed in the graft persist in the host for long 
periods post-BMT using the major histocompatibility complex (MHC)-mismatched model of 
BMT. Lethally irradiated C3H (H-2k) recipient mice received 10×106 TCD-BM cells from 
B6.Ly-5a (H-2b,CD45.1) mice with/without 1 – 2×106 spleen cells from B6 (H-2b,CD45.2) 
mice. All of the recipients of allogeneic C3H TCD-BM cells from B6 mice and syngeneic 
mice survived and were resistant to induction of GVHD. Although 100% of the animals that 
received allogeneic BM plus 2×106 spleen cells died by day 35 with clinical and 
histopathological signs of severe GVHD, the recipients of allogeneic BM plus 1×106 spleen 
cells (BM plus Sp cells) showed mild clinical signs of GVHD and 60% survived by day 120 
(Fig. 1A); the following experiment was performed in this setting. Flow cytometric analysis 
of donor cell chimerism in the spleen 3 weeks after allogeneic BMT showed that 98.8% ± 
0.7% of spleen cells were derived from the donor in mice, thus confirming complete donor 
cell engraftment. Host Tregs, as determined by CD4+Foxp3+H-2k+, were not detected in the 
spleen on day 21 post-transplantation (data not shown). On day 21 post-transplantation, the 
majority of CD4+Foxp3+ Tregs were derived from CD45.2+ splenic T cells (83.4% ± 2.2%), 
suggesting that splenic T cell-derived Tregs underwent homeostatic and/or alloantigen-driven 
expansion (Fig. 1B) and the absolute number of Tregs in the spleens of the recipients of BM 
plus Sp cells was significantly higher than in TCD-BM recipients. From day 21 onward, due 
to GVHD-induced lymphopenia, the absolute number of Tregs in the spleens of recipients of 
BM plus Sp cells was lower than in TCD-BM recipients (Fig. 1C). The rate of CD45.2+ 
splenic T cell-derived Tregs in CD4+Foxp3+ Treg decreased gradually and most 
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CD4+Foxp3+ Treg were CD45.1+ BM-derived (93.2%) on day 125 post-transplantation (Fig. 
2A). The rate of CD45.1+ BM-derived Tregs in the mesenteric lymph nodes (MLN) was also 
increased and became dominant in the late post-transplant period (Fig. 2B). To exclude 
strain-dependent artifacts, we next evaluated the kinetics of Treg reconstitution in the B6 
(H-2b) into C3.SW (H-2b) MHC-compatible, multiple minor histocompatibility antigen 
(miHA)-incompatible model of SCT. The kinetics of Treg reconstitution in the spleen was 
similar and most CD4+Foxp3+ Tregs were derived from CD45.1+ BM (97%) on day 90 
post-transplantation (Fig. 2C). These findings indicated that the peripheral Treg pool was 
restored first by expanded splenic T cell-derived mature Treg and then by new Tregs 
generated from donor BM-derived progenitors. Next, to examine the function of newly 
arising Tregs, purified CD4+CD25+ T cells on day 120 post-transplantation were assessed for 
their ability to inhibit proliferation by responding syngeneic CD4+CD25– B6 T cells. Their 
suppressive activity was virtually indistinguishable from that of Tregs obtained from normal 
B6 mice (Fig. 2D). Taken together, Tregs generated from donor BM-derived progenitors 
comprise the long-term peripheral Treg pool and exhibit immunosuppressive activity. 
 
CSA, but not mTORinhibitors, hampered reconstitution of BM-derived Treg 
Coenen et al. reported that 28 days of CSA administration hampered Treg homeostasis 
in normal mice (28). We examined whether use of CSA for an extended period affected the 
long-term peripheral Treg pool after BMT. C3H recipient mice were transplanted from B6 
donor mice (as shown in Fig. 1) and received i.p. injection of CSA, mTOR inhibitor 
(rapamycin; RAPA), or vehicle control daily from day 0. We analyzed the effects of CSA and 
RAPA on the Treg compartment at 21, 35, 56, and 110 days post-HCT. Mice treated with 
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CSA or RAPA showed the same Treg reconstitution pattern as those treated with vehicle 
solution. On day 21 post-transplantation, the majority of CD4+Foxp3+ Tregs in the spleen 
were CD45.2+ splenic T cell-derived cells but the Treg compartments were dominated by 
BM-derived cells on days 56 and 110 post-transplantation in all three groups (Fig. 3A). In the 
MLN, these three groups also showed similar Treg reconstitution kinetics (Fig. 3B). There 
were no differences in the absolute numbers of Treg among the three groups on day 21. From 
day 21 onward, however, the absolute numbers of Tregs in the CSA-treated mice were lower 
than those in control mice both in the spleen (day 56: 1.3 ± 0.4 vs. 4.6 ± 0.8×105, P < 0.01, 
day 110: 10.4 ± 1.4 vs. 16.7 ± 2.4×105, P < 0.05, Fig. 4A) and in the MLN (day 56: 1.3 ± 0.5 
vs. 7.4 ± 1.6×104, P < 0.03, day 110: 2.9 ± 1.0 vs. 4.9 ± 1.9×105, P = 0.46, Fig. 4B). 
Especially in the thymus, mice treated with CSA showed a marked reduction in the absolute 
numbers of Tregs compared to those treated with vehicle control (day 110: 4.6 ± 1.8 vs. 25.7 
± 5.0×104, P < 0.01, Fig. 4C). In contrast to CSA, mice treated with RAPA showed no 
reduction in the absolute numbers of Tregs and no differences compared to control mice in 
the spleen or MLN at any time point post-transplantation (Fig. 4A, B). The absolute numbers 
of newly arising Tregs in the thymus were also not reduced in mice treated with RAPA (Fig. 
4C). We next examined the effects of another mTOR inhibitor, everolimus (RAD), which 
exhibits greater polarity than RAPA and has been approved in Europe for use as an 
immunosuppressant for prevention of cardiac and renal allograft rejection. Reconstitution of 
newly arising Tregs in the thymus was not impaired in mice treated with RAD, and there 
were no differences in the absolute numbers of spleen Tregs compared to control mice on day 
110 (spleen: 15.4 ± 2.5 vs. 16.6 ± 2.4×105, P = 0.73, Supplemental data Fig. 1A, thymus: 
17.4 ± 3.2 vs. 25.7 ± 5.0×104, P = 0.26, Supplemental data Fig. 1B). These findings 
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suggested that CSA, but not mTOR inhibitors, hampered the long-term reconstitution of 
BM-derived Tregs. 
 
CSA, but not mTOR inhibitors, increased liability to chronic GVHD 
Recent studies revealed the association of reduced Treg frequency in patients with 
chronic GVHD. In the present study, we examined histopathological change in CSA-treated 
mice where reconstitution of BM-derived Tregs was impaired. The skin of CSA-treated mice 
showed pathogenic features of chronic GVHD (Fig. 5A), and pathogenic scores revealed 
significantly exacerbated chronic GVHD pathology compared to those treated with vehicle 
control (Fig. 5B; 5.5 ± 0.8 vs. 1.6 ± 0.3, P < 0.01). A dry mouth is one of the distinctive 
features of chronic GVHD. Lymphocytic inflammation, fibrosis, and atrophy of acinar tissue 
were observed in the salivary glands of CSA-treated mice (Fig. 5A) and pathological scores 
were significantly higher in CSA-treated mice than in the controls (Fig. 5C; 4.0 ± 0.5 vs. 1.8 
± 0.1, P < 0.01). CSA-treated mice showed bile duct injury and fibrosis in the portal area and 
peripheral mononuclear cell infiltration in the liver and pathological scores of the liver also 
tended to be worse in CSA-treated mice, as compared to those treated with vehicle control, 
although it was not statistically significant (Fig 5D). In contrast to CSA, mice treated with 
RAPA showed no pathogenic features of chronic GVHD and there were no differences in 
pathogenic skin and salivary gland scores, as compared to control mice (Fig. 5B skin 0.75 ± 
0.4 vs. 1.6 ± 0.3, P = 0.18, Fig. 5C salivary gland ; 1.25 ± 0.2 vs.1.78 ± 0.1, P = 0.08). 
Immunohistochemical staining for Foxp3 and CD3 revealed that CD3+ T cells infiltrated in 
the skin tissue of all three groups, and RAD-treated mice showed abundant infiltration by 
CD3+ T cells and Foxp3+ cells (Fig. 6A). In contrast to RAD, Foxp3+ cells were scarcely 
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found in skin tissue of CSA-treated mice. The ratio of Foxp3 Tregs per 100 CD3+ 
lymphocytes in the skin tissue of CSA-treated mice was significantly lower than those in 
RAD-treated mice (3.23 ± 0.4 vs. 19.5 ± 4.4, P < 0.05). CSA-treated mice tended to show 
poorer survival, as compared to those treated with mTOR inhibitors or vehicle control (CSA 
27.6% vs. control 54.2%, RAD 57.1%, RAPA 61.5%, P = 0.28, Supplemental data Fig. 2). 
These findings suggested that CSA, but not mTOR inhibitors, hampered the reconstitution of 
BM-derived Treg and increased liability to chronic GVHD.  
We next tested liability to chronic GVHD in CSA-treated mice using adoptive transfer 
experiments. Previously, Sakoda et al. demonstrated that impaired thymic negative selection 
of the recipients permitted the emergence of pathogenic T cells that cause chronic GVHD 
(Fig. 7A) (23). Lethally irradiated C3H recipients were reconstituted with TCD BM from 
MHC class II-deficient (H2-Ab1−/−) B6 mice ([H2-Ab1−/− → C3H]). These mice developed 
disease conditions that showed all of the clinical and histopathological features of human 
chronic GVHD. CD4+ T cells isolated from chronic GVHD mice ([H2-Ab1−/− → C3H] 
CD4+ T cells) cause chronic GVHD when B6 antigens are provided by hematopoietic cells 
in the absence of B6 antigen expression on target epithelium ([B6 → C3H] chimeras) (23). In 
the current study, C3H mice were transplanted from B6 donors as shown in Fig. 1 and were 
orally administered CSA, RAPA, or vehicle solution until 60 days post-BMT, when none of 
the recipients showed significant signs of chronic GVHD. To test liability to chronic GVHD, 
these C3H recipient mice with B6-derived antigen presenting cells received adoptive transfer 
of [H2-Ab1−/− → C3H] CD4+ T cells (Fig. 7B). As shown in Fig. 7C and 7D, adoptive 
transfer of pathogenic CD4+ T cells caused severe weight loss (CSA 81.1 ± 4.1% vs. control 
94.5 ± 2.1%, P < 0.05, CSA 81.1 ± 4.1% vs. RAPA 98.9 ± 1.5%, P < 0.01) and chronic 
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GVHD in CSA-treated mice, with a mortality rate of 83%. RAPA-treated mice and controls 
showed resistance to induction of chronic GVHD by transfer of pathogenic CD4+ T cells; the 
survival rate on day 62 after adoptive transfer was 100%. Taken together, these data 
demonstrated that CSA, but not mTOR inhibitors, increased liability to chronic GVHD.
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Discussion 
Patients with chronic GVHD have a lower frequency of Tregs when compared with 
patients without chronic GVHD (29-32). Experimental BMT demonstrated that Tregs in the 
inoculum can prevent acute GVHD when injected together with donor T cells (12-14), 
however, it is not known whether Tregs in the grafts persist into the late post-transplant 
period and play a role in preventing chronic GVHD. Mastuoka et al. prospectively monitored 
CD4+ T cell subsets and showed that thymic generation of naïve Treg was markedly impaired 
and Treg levels subsequently declined in patients with prolonged CD4+ lymphopenia (32). 
This resulted in a relative Treg deficiency, which was associated with a high incidence of 
extensive chronic GVHD. In the present study, we monitored Treg reconstitution kinetics in 
the spleen, MLN, and thymus according to two subsets, T cells derived from 
peripheral-expanded mature T cells and newly arising T cells from bone marrow stem cells, 
using two mouse BMT models because this is difficult to examine in a human setting. The 
results indicated that host Tregs disappeared rapidly in mice receiving allogeneic T cells early 
in the early post-transplant period, consistent with a previous report (33). In addition, this 
study showed that splenic T cell-derived Treg initially occupy a niche in lymphopenic 
transplantation recipients, suggesting that mature Treg underwent homeostatic and/or 
alloantigen-driven expansion. However, the donor splenic T cell-derived Treg pool 
contracted gradually and Tregs generated from donor BM-derived progenitors comprised the 
long-term peripheral Treg pool. The BM-derived Treg compartment was functionally 
competent, as determined by in vitro lymphoid suppression, indicating that these cells play a 
role in post-BMT immune tolerance. 
Coenen et al. reported that 28 days of treatment with CSA resulted in a reduction in 
16 
 
thymic generation of CD4+Foxp3+ T cells and peripheral CD25+Foxp3+ T cells in normal 
mice (28). We assessed whether CSA affects the peripheral Treg pool after allogeneic BMT; 
on day 21, there were no differences in the absolute numbers of Tregs among three groups, 
and CSA had no impact on early Treg reconstitution. Consistent with our observations, 
Setoguchi et al. reported that in contrast to the requirement of IL-2 for physiological 
expansion of CD4+CD25+ Treg cells in normal nonlymphopenic mice, homeostatic 
proliferation in a lymphopenic environment appears to be IL-2-independent (19). Zeiser et al. 
also reported that CSA administration has only a minor impact on the expansion of 
adoptively transferred CD4+CD25+ T cells on day 7 post-transplantation (34). However, 
whether prolonged use of CSA affects the long-term peripheral Treg pool has not been 
reported. Our data showed that CSA, but not mTOR inhibitors, hampered the long-term 
reconstitution of BM-derived Tregs. The numbers of Tregs in the spleen, thymus and tissue 
were significantly reduced in mice receiving CSA in comparison to those receiving mTOR 
inhibitors or PBS on day 110. CSA blocks nuclear factor of activated T cells (NF-AT) 
translocation into the nucleus by inhibiting calcineurin phosphatase activity (35). CSA 
inhibits the thymic generation of Tregs by impairment of TCR signaling and by reducing 
NF-AT-dependent Foxp3 promoter activity (36). In contrast, rapamycin-sensitive 
downstream targets of PI3K are IL-2-independent, and rapamycin affects neither the initial 
signal transduction upon TCR triggering nor the thymic generation of Treg (37). 
Immunosuppressive drugs have different mechanisms of promoting immune suppression and 
our data revealed different effects on the long-term peripheral Treg pool after allogeneic 
BMT. 
Although mouse models of chronic GVHD have provided important insights into 
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pathophysiology of this disease, one factor that confounds the translation of findings in 
mouse models to the human disease is that time course of development of chronic GVHD is 
more rapid in most mouse models than in human. Another factor is that most patients are 
given immunosuppressive therapy to prevent acute GVHD(38), and these medications might 
influence the development of chronic GVHD. In this study, histopathological examination 
revealed that CSA-treated mice showed pathogenic features of chronic GVHD, while those 
treated with mTOR inhibitors showed no significant differences compared with control mice. 
This is the first report that long-term use of CSA induces chronic GVHD in transplant 
recipient mice. This may have been due to induction of autoreactive T cells by CSA(39, 40). 
Wu et al. reported that CSA contributes to chronic GVHD in experimental models, which 
was ascribed to the disruption of clonal deletion mechanisms in the thymus, resulting in the 
export of autoreactive T cells (41). The present study demonstrated another mechanism by 
which CSA impaired Treg reconstitution. Adoptive transfer of the pathogenic CD4+ T cells 
caused severe chronic GVHD in CSA-treated mice, while mTOR inhibitor-treated and 
control mice showed resistance to induction of chronic GVHD. These findings suggest that 
the increased liability to chronic GVHD in CSA treated mice might be due to limited 
reconstitution of BM-derived Treg cells; further mechanistic studies will be required to 
determine if this is truly causative rather than merely an association. 
Here, we assessed the differential effects of CSA and mTOR inhibitors on the long-term 
peripheral Treg pool after allogeneic BMT. Our findings indicated that, in contrast to mTOR 
inhibitors, CSA compromises homeostasis in peripheral immune compartments and thymic 
generation of CD4+CD25+Foxp3+ T cells. GVHD prophylaxis with mTOR inhibitor and 
calcineurin inhibitor failed to reduce chronic GVHD (11, 42-45). The choice of calcineurin 
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inhibitor-free GVHD prophylaxis with mTOR inhibitors, such as mTOR inhibitors plus IL-2 
(16) or mTOR inhibitors plus ATG (46) may have important implications for the control of 
chronic GVHD after BMT. 
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Figure legends 
 
Figure 1. Regulatory T cell reconstitution after allogeneic BMT. 
Lethally irradiated C3H(H-2k) recipient mice received 10×106 T cell-depleted bone marrow 
(TCD-BM) cells from B6.Ly-5a (H-2b,CD45.1) mice with/without 1 – 2×106 spleen cells 
from B6 (H-2b,CD45.2) mice. The syngeneic group received transplantation from C3H mice. 
(A) Survival: the recipients of allogeneic BM plus 1×106 spleen cells (BM plus Sp cells) 
showed a survival rate of 60% by day 120. Open circle, syngeneic; closed circle, TCD-BM 
cells only; triangle, -with 1×106 spleen cells; square, -with 2×106 spleen cells. (B) Origin of 
CD4+Foxp3+ Treg in the spleen on day 21 post-transplantation: CD45.2+ splenic T 
cell-derived (white bars) and CD45.2– BM-derived (black bars) are shown. (C) The absolute 
numbers of Treg in the recipients of BM plus Sp cells (triangles) and TCD-BM (closed 
circles) are shown. Each group consisted of 7 – 25 mice. The means (± SE) of each group are 
shown. Data are from a representative of at least three independent experiments. *P < 0.05; 
**P < 0.01. 
 
Figure 2. Donor BM-derived progenitors comprise the long-term peripheral Treg pool. 
Lethally irradiated C3H recipients were transplanted as in Fig. 1: (B6 → C3H). The rates of 
CD45.2+ spleen cell-derived (broken lines) and CD45.2– BM-derived (solid lines) Treg in 
CD4+Foxp3+ Treg are shown. Spleen (A) and mesenteric lymph nodes (MLN) (B) were 
isolated from (B6 → C3H) mice at various time points after BMT and cells were analyzed by 
FACS. (C) Lethally irradiated C3.SW (H-2b) recipients were transplanted from B6 (H-2b) 
donors. The rates of CD45.2+ splenic T cell-derived (broken lines) and CD45.2– BM-derived 
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(solid lines) Treg in CD4+Foxp3+ Treg in the spleen are shown. Each group consisted of 20 – 
23 mice. The means (± SE) of each group are shown. Data are from a representative of at 
least two independent experiments. (D) CD25+CD4+ Treg were purified from the spleens of  
(B6 → C3H) mice (on day 120) or naïve B6 (WT). B6 CD4+CD25– T cells (Tcon) together 
with various numbers of Treg were cultured with irradiated C3H CD11c+ DC as stimulators 
for 72 h. Proliferative activities were determined by monitoring 3H-thymidine uptake. 
 
Figure 3. Effects of CSA and mTOR inhibitors on the Treg compartment. 
Lethally irradiated C3H recipients were transplanted from B6 donor mice as shown in Fig. 1 
and received i.p. injections of CSA (closed squares), mTOR inhibitor (rapamycin, RAPA; 
open triangles), or vehicle control (open squares) daily from day 0 to 110. The rates of 
CD45.2+ splenic T cell-derived (broken lines) and CD45.2– BM derived (solid lines) Treg in 
CD4+Foxp3+ Treg are shown. Spleen (A) and mesenteric lymph nodes (MLN) (B) were 
isolated from (B6 → C3H) mice at various time points after BMT and cells were analyzed by 
FACS. Each group consisted of 16 – 23 mice. The means (± SE) of each group are shown. 
Data are from a representative of at least two independent experiments.  
 
Figure 4. CSA, but not mTOR, inhibitors hampered reconstitution of BM-derived Treg. 
(B6 → C3H) mice received i.p. injections of CSA (black bars), mTOR inhibitor (rapamycin, 
RAPA; gray bars), or vehicle control (white bars) daily from day 0 to 110. The absolute 
numbers of Treg in the spleen (A), MLN (B), and thymus (C) are shown. Each group 
consisted of 19–26 mice. The means (± SE) of each group are shown. Data are from a 
representative of at least two independent experiments. *P < 0.05; **P < 0.01. 
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Figure 5. CSA, but not mTOR, inhibitors increased the likelihood of chronic GVHD. 
(A) Histological findings of the skin (a – d), liver (e – h), and salivary glands (i – l) (on day 
120) from (B6 → C3H) mice given CSA, mTOR inhibitor (RAPA, RAD), or vehicle control. 
Sclerodermatous skin changes, such as epidermal atrophy, fat loss, follicular dropout, and 
dermal thickness (b); fibrosis in the portal area and peripheral mononuclear cells infiltrates in 
the liver (f); and fibrosis and atrophy of acinar tissue in the salivary glands (j) were observed 
(original magnification: ×100) Pathological scores of skin (B), salivary gland (C) and liver 
(D) . The data are expressed as means ± SE. Data are from a representative of at least two 
independent experiments. *P < 0.05; **P < 0.01. 
 
Figure 6. CSA, but not mTOR, reduces Treg infiltration in skin tissue. 
(A) Lethally irradiated C3H recipients were transplanted from B6 donor mice as shown in Fig. 
1 and received vehicle control (a, d), CSA (b, e), or mTOR inhibitor (RAD; c, f), daily from 
day 0 to 120. Immunohistochemical staining was performed using anti-Foxp3 (a-c) and 
anti-CD3 (d-f) antibodies on day 120. Arrows indicate Foxp3 positive cells. (B) The ratio of 
Foxp3 Tregs per 100 CD3+ lymphocytes. The number of CD3 and Foxp3 cells was counted 
in all the high-power ﬁelds. Results are expressed as mean ± SD. Pictures and data are from a 
representative of two independent experiments. (n = 3-4 per group). *P < 0.05. 
 
Figure 7. Adoptive transfer of pathogenic CD4+ T cells caused severe chronic GVHD. 
(A) Lethally irradiated C3H recipients were reconstituted with TCD BM from MHC class 
II-deficient (H2-Ab1−/−) B6 mice. These mice developed chronic GVHD and CD4+ T cells 
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isolated from chronic GVHD mice ([H2-Ab1−/− → C3H] CD4+ T cells) were primarily donor 
reactive. These pathogenic CD4+ T cells cause chronic GVHD when B6 antigens are 
provided by hematopoietic cells in the absence of B6 antigen expression on target epithelium 
([B6 → C3H] chimeras). (B) C3H recipient mice were transplanted from B6 donors as shown 
in Fig. 1 and were received CSA, RAPA, or vehicle solution until 60 days post-BMT. These 
C3H recipient mice received adoptive transfer of [H2-Ab1−/− → C3H] CD4+ T cells. Body 
weight change (C) and overall survival (D). Data from three similar experiments are 
combined (n = 8 -12 per group). The data are expressed as means ± SE. *P < 0.05; **P < 
0.01. 
 
 
Supplemental data Figure 1. Another mTOR inhibitor, everolimus (RAD), allowed 
reconstitution of BM-derived Treg. 
(B6 → C3H) mice received CSA (black bars), the mTOR inhibitor everolimus (RAD; gray 
bars), or vehicle control (white bars) daily from day 0 to 110. The absolute numbers of Treg 
in the spleen (A) and thymus (B) are shown. Each group consisted of 4 – 10 mice. The means 
(± SE) of each group are shown. Data are from a representative of at least two independent 
experiments. *P < 0.05; **P < 0.01. 
 
Supplemental data Figure 2.  Kaplan-Meier curves showing the survival of recipient 
mice administered CSA, RAPA, RAD or vehicle solution.  
Lethally irradiated C3H recipients were transplanted from B6 donor mice as shown in Fig. 1 
and received CSA, RAPA, RAD, or vehicle control, daily from day 0 to 120. Data from two 
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similar experiments are combined. ●, control, n=45; ■, CSA, n=44; ○, RAPA, n=34; ▲, 
RAD, n=21. There was no significant difference among the four groups. 
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